prof. dr. Triana Lobatón Ortega
- Work address
-
C. Heymanslaan 10, ingang 12 - verdieping 6
9000 Gent - Triana.LobatonOrtega@UGent.be
- ORCID iD
-
0000-0003-1817-7704
Show
Sort by
-
Anti-CD74 IgA antibodies show diagnostic potential for axial spondyloarthritis but are not associated with microscopic gut inflammation
-
- Journal Article
- A1
- open access
Distinct immune modulatory roles of regulatory T cells in gut versus joint inflammation in TNF-driven spondyloarthritis
-
- Journal Article
- A1
- open access
Comparison of short- and long-term effectiveness between anti-TNF and ustekinumab after vedolizumab failure as first-line therapy in Crohn’s disease : a multi-center retrospective cohort study
-
- Journal Article
- A1
- open access
SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders : a prospective, real-life Belgian cohort study - the BELCOMID study
-
The impact of vedolizumab and ustekinumab on articular extra-intestinal manifestations in inflammatory bowel disease patients : a real-life multicentric cohort study
-
- Journal Article
- A1
- open access
Effect of 5-hydroxytryptophan on fatigue in quiescent inflammatory bowel disease : a randomized controlled trial
-
- Journal Article
- A1
- open access
Endoscopic postoperative recurrence in Crohn's disease after curative ileocecal resection with early prophylaxis by anti-TNF, vedolizumab or ustekinumab : a real-world multicenter European study
-
- Journal Article
- A1
- open access
Role of integrin expression in the prediction of response to vedolizumab : a prospective real‐life multicentre cohort study
-
Infliximab re-challenge : could it be an option in refractory IBD patients?
-
A randomized placebo controlled clinical trial with 5-hydroxytryptophan in patients with quiescent Inflammatory Bowel Disease and fatigue (Trp-IBD)